



#25
SB
7/8/00

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Evans et al.
Appl. No. : 08/487,283
Filed : June 7, 1995
For : METHODS AND COMPOSITIONS FOR THE
TREATMENT OF INFLAMMATORY DISEASES
Examiner : P. Gambel
Group : 1644

Commissioner of Patents and Trademarks
Washington, D.C. 20231

RESPONSE TO RESTRICTION REQUIREMENT

In the Office Action dated December 15, 1999, the Examiner entered a six-way restriction requirement as follows:

Group I -- Claims 1-8, 18-23, 25-27, and 29-31

Group II -- Claims 9-12 and 28

Group III -- Claim 13

Group IV -- Claim 14

Group V -- Claim 15

Group VI -- Claims 16-17

In response to this restriction requirement, applicants elect the claims of Group I, i.e., Claims 1-8, 18-23, 25-27, and 29-31, for further prosecution in this application.

This election is made with traverse since applicants believe that the claims of Groups I-V inclusive can be readily examined in this pre-GATT application since all of these claims relate, in one way or another, to anti-C5 antibodies. As stated in §803 of the MPEP, "[t]here must be a serious burden on the examiner if restriction is required." Applicants respectfully

✓